187 related articles for article (PubMed ID: 38127915)
1. Resiliency outcomes after participation in an asynchronous web-based platform for adults with neurofibromatosis: The NF-Web study.
Wang KE; Vranceanu AM; Lester EG
PLoS One; 2023; 18(12):e0295546. PubMed ID: 38127915
[TBL] [Abstract][Full Text] [Related]
2. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.
Vranceanu AM; Merker VL; Plotkin SR; Park ER
J Neurooncol; 2014 Oct; 120(1):103-9. PubMed ID: 25022450
[TBL] [Abstract][Full Text] [Related]
3. Adaptation of a Live Video Mind-Body Program to a Web-Based Platform for English-Speaking Adults With Neurofibromatosis: Protocol for the NF-Web Study.
Lester EG; Hopkins SW; Popok PJ; Vranceanu AM
JMIR Res Protoc; 2021 Jun; 10(6):e27526. PubMed ID: 34110294
[TBL] [Abstract][Full Text] [Related]
4. Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program.
Lester EG; Macklin EA; Plotkin S; Vranceanu AM
J Neurooncol; 2020 Apr; 147(2):451-457. PubMed ID: 32078086
[TBL] [Abstract][Full Text] [Related]
5. The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.
Presciutti AM; Lester EG; Woodworth EC; Greenberg J; Bakhshaie J; Hooker JE; McDermott KA; Vranceanu AM
J Neurooncol; 2023 Jul; 163(3):707-716. PubMed ID: 37440099
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial.
Fishbein NS; Vranceanu AM; Mace RA
J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531
[TBL] [Abstract][Full Text] [Related]
7. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
8. The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis.
Zale EL; Pierre-Louis C; Macklin EA; Riklin E; Vranceanu AM
J Neurooncol; 2018 Apr; 137(2):321-329. PubMed ID: 29275505
[TBL] [Abstract][Full Text] [Related]
9. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
10. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
[TBL] [Abstract][Full Text] [Related]
11. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
[TBL] [Abstract][Full Text] [Related]
12. Early feasibility testing of a web-based mind-body resiliency program for adults with neurofibromatosis: The NF-Web study.
Lester EG; Fishbein NS; Peterson A; Vranceanu AM
PEC Innov; 2022 Dec; 1():100076. PubMed ID: 37213775
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis: part 2--clinical management.
Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
[TBL] [Abstract][Full Text] [Related]
14. Psychological resiliency explains the relationship between emotional distress and quality of life in neurofibromatosis.
Mace RA; Doorley J; Bakhshaie J; Cohen JE; Vranceanu AM
J Neurooncol; 2021 Nov; 155(2):125-132. PubMed ID: 34570301
[TBL] [Abstract][Full Text] [Related]
15. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
[TBL] [Abstract][Full Text] [Related]
16. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
17. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
[TBL] [Abstract][Full Text] [Related]
18. Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial.
Greenberg J; Carter S; Lester E; Funes CJ; Macklin EA; Plotkin S; Vranceanu AM
J Neurooncol; 2019 Dec; 145(3):561-569. PubMed ID: 31677033
[TBL] [Abstract][Full Text] [Related]
19. Impact of mind-body treatment interventions on quality of life in neurofibromatosis patients: A systematic review and meta-analysis.
Wei G; Farooq J; Kumar A
Dermatol Ther; 2021 Jan; 34(1):e14613. PubMed ID: 33258517
[TBL] [Abstract][Full Text] [Related]
20. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]